AUSTIN, Texas, Jan. 19, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 7th Annual Life Science CEO Forum on January 25-26 in Atlanta GA at the Westin Buckhead Hotel. Valerie Palmieri, President and Chief Executive Officer of Vermillion, will present on "The Plight of Ovarian Cancer, a Pelvic Mass Care Pathway Solution and Getting Paid," highlighting the use of Vermillion's OVA1® diagnostic test, at 5:00 PM EST on January 25th. Ms. Palmieri will be joined in the conference by speakers representing such diverse companies as Genzyme, J&J, Pfizer and Sun Pharma.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company's lead diagnostic in the United States, OVA1, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach and is available through Vermillion's wholly owned subsidiary, ASPiRA LABS. OVA1, which was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Liquid Biopsy Assay, represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
About the Annual Life Sciences CEO Forum
The 7th Annual Life Science Chief Executive Officer Forum will provide executives with a platform for education, discussion and debate surrounding the progression of the life science industry, as well as strategies for maintaining a competitive advantage. Keynote presentations will track the evolution of the industry over the past decade as well as provide projections and insights into future growth and development across a wide range of therapeutic areas, providing participants with strategic information needed as portfolios continue to advance and evolve. Additional presentations will focus on topics including healthcare policy and regulatory reforms, economic models impacting the industry, as well as sessions on recent M&A and opportunities in unique and beneficial partnership structures. For more information, go to http://www.q1productions.com/conferencepost/ceoforum/.
Investor Relations Contact:
LifeSci Advisors LLC
SOURCE Vermillion, Inc.